Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor (Q40918961)

24 September 2017

Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor (English)

1 reference

24 September 2017

0 references

0 references

2

C Nathan

1 reference

24 September 2017

J Zhu

1

1 reference

PubMed ID

10556576

24 September 2017

A Ding

series ordinal

3

1 reference

24 September 2017

1 September 1999

1 reference

Biochimica et Biophysica Acta

24 September 2017

1 reference

24 September 2017

1451

1 reference

24 September 2017

219-223

1 reference

24 September 2017

2-3

1 reference

Secretory products of macrophages

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Knowledge of cellular receptors for bacterial endotoxin--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

CD11/CD18 leukocyte integrins: new signaling receptors for bacterial endotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Distribution of secretory leukoprotease inhibitor in the human nasal airway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Functional reconstitution of an immunoglobulin antigen receptor in T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4889%2899%2900111-1

7 January 2021

10.1016/S0167-4889(99)00111-1

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

10556576